| 產(chǎn)品名稱 | SCIO 469 - Talmapimod |
| 產(chǎn)品貨號 | Axon 1671 CAS [309913-83-5] MF C27H30ClFN4O3MW 513.00 Purity: 98% Soluble in DMSO Description Orally available and selective inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK), with a 10-fold selectivity for p38α over p38β and 2000-fold over 20 other kinases; potential agent with immunomodulating, anti-inflammatory and antineoplastic activities References Certificates Categories Extra info SN Nikas and AA Drosos. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004, 5(11), 1205-1212. ? SN Nikas and AA Drosos. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004, 5(11), 1205-1212. ? T Navas et al. The p38 MAPK inhibitor SCIO-469 enhances the apoptotic and anti-proliferative effects of proteasome inhibitors MG132 and PS341 (Velcade) in multiple myeloma cells. Proc. Amer. Assoc. Cancer Res, 2004, Vol.?Abs. #3350. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Immunology Pain & Inflammation MAPK (p38) MAPK EC 2.7.11.24 MAPK inhibitor (p38 specific) Chemical name 2-(6-chloro-5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide Parent CAS No. [309913-83-5] Order Size Unit Price Stock 5 mg €105.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
SCIO 469 - TalmapimodAxon 1671 CAS [309913-83-5] MF C27H30ClFN4O3
Description
Orally available and selective inhibitor of p38 mitogen-activated protein (MAP) kinase (MAPK), with a 10-fold selectivity for p38α over p38β and 2000-fold over 20 other kinases; potential agent with immunomodulating, anti-inflammatory and antineoplastic activities
MAPK inhibitor (p38 specific)
Chemical name2-(6-chloro-5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide Parent CAS No.[309913-83-5] |
| 產(chǎn)品資料 |
